Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids.
Tumorigenic transformation of SV40-immortalized human uroepithelial cells (SV-HUC) after transfection with EJ/ras was previously reported to be a rare event. To test the hypothesis that ras transformation requires loss of suppressor genes, somatic cell hybrids were generated between a rare tumorigenic transformant and an isogeneic nontumorigenic EJ/ras transfectant obtained in the same experiment. Both parental cell lines, as well as all hybrid progeny, expressed mutant p21 ras protein, but injections of three such independent hybrids into athymic nude mice at passage (P) 4 demonstrated that tumorigenicity was suppressed at 20 of 22 sites. Two tumors developed, after a relatively long 17-week latent period, as compared with a 4-week latent period for the tumorigenic parent. All three hybrids produced tumors at P8, but these showed different latent periods (3-14 weeks). Revertant hybrid tumors were high-grade carcinomas. Cell lines derived from these tumors expressed mutant p21 ras and retained at least 1 EJ/ras integration site. Karyotypic analysis of six independent hybrid tumor revertants showed that each had a unique clonal karyotype. Losses of two or more homologues of 1p, 3p, 4, 8, 10p, 11p, 13q, and 18 were identified in one or more tumorigenic revertants. Losses of all these chromosomes were previously associated with transformation of SV-HUC by EJ/ras, but were also associated with chemical transformation of SV-HUC in tumors that did not express mutant ras. Genetic losses involving most of these chromosomes have also been identified in clinical bladder cancers (i.e., 1p, 3p, 8, 11p, 13 and 18q). These data show that expression of EJ/ras does not negate or significantly alter requirements for multiple genetic losses in HUC tumorigenesis.
Pratt
C I
CI
Cellular and Molecular Biology Program, University of Wisconsin Clinical Cancer Center, Madison 53792.
Wu
S Q
SQ
Bhattacharya
M
M
Kao
C
C
Gilchrist
K W
KW
Reznikoff
C A
CA
D000818:Animals; D002277:Carcinoma / Q000235:genetics*; D002461:Cell Line, Transformed; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002872:Chromosome Deletion; D002877:Chromosomes, Human; D002878:Chromosomes, Human, Pair 1; D002880:Chromosomes, Human, Pair 11; D002882:Chromosomes, Human, Pair 13; D002887:Chromosomes, Human, Pair 18; D002893:Chromosomes, Human, Pair 3; D002898:Chromosomes, Human, Pair 8; D004847:Epithelial Cells; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016153:Genes, Suppressor; D011905:Genes, ras; D006801:Humans; D006822:Hybrid Cells; D051379:Mice; D008819:Mice, Nude; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis; D013539:Simian virus 40; D014162:Transfection; D001743:Urinary Bladder / Q000166:cytology; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)